The rise of biosimilars is great news for overburdened healthcare systems, but it’s a very different proposition to a simple generic.

Alternative delivery routes for large-molecule drugs are sorely needed – could a new consortium lead the way?

Sitting Down With… David Pyott, Former Chairman of the Board and Chief Executive Officer of Allergan, Inc.

When it comes to anti-counterfeiting, you need to go beyond legislation, think ahead, and harness the competitive edge that serialization can offer.

The technology has barely changed over the last 30 years – surely, it’s time for some long overdue innovation.

In the midst of wrangles over biosimilars naming and interchangeability, let’s not forget the key benefit...

Click chemistry creates biocompatible hydrogels for drug delivery and tissue engineering

How much do the public really know about pharma R&D?

Some drug shortage prevention plans fail, while others succeed. Why? ISPE helps companies find the answer

Scientists find a way to ‘fingerprint’ the structure of a monoclonal antibody